MedPath

Lactate and Complications in Cytoreduction Surgery for Peritoneal Carcinomatosis

Completed
Conditions
Lactacidemia and Complications
Registration Number
NCT04307654
Lead Sponsor
Hospital General Universitario de Castellón
Brief Summary

Serum lactate is a risk factor for postoperative complications in patients undergoing cytoreduction surgery in peritoneal carcinomatosis

Detailed Description

Background. Cytoreduction surgery has been developed as a treatment of peritoneal carcinomatosis. However, this surgery is associated with important complications. The present study attempts to assess the relationship between lactacidemia levels and the rate of associated complications in patients undergoing cytoreduction surgery during the immediate postoperative period in a critical unit.

Methods. Retrospective observational study. 57 patients underwent cytoreduction surgery during the years 2014 and 2015 at the General University Hospital of Castellón. All patients were admitted to the critical unit immediately after surgery. Lactacidemia levels at the time of admission and discharge from the critical unit were collected. Post-surgical complications that appeared during the stay in the critical unit were recorded and classified according to the Clavien-Dindo classification.

Lactacidemia levels were still significantly higher in this group at the time of discharge.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
57
Inclusion Criteria
  • patients diagnosed with peritoneal carcinomatosis who underwent cytoreduction surgery in the Multidisciplinary Unit of Abdomino-Pelvic Oncology Surgery (MUAPOS) of the University General Hospital of Castellón.
Exclusion Criteria
  • patients without lactic acid levels in the register.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Postoperative complications2014-2016

complications in patients undergoing cytoreduction surgery during the immediate postoperative period in the Intensive Care Unit (ICU) at the General Hospital of Castellón (HGCS) between 2014 and 2016.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath